PharmaPoint: Meningococcal Vaccines-Australia Drug Market:Industry Analysis Report

200 views

Published on

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
200
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

PharmaPoint: Meningococcal Vaccines-Australia Drug Market:Industry Analysis Report

  1. 1. PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022 GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines Australia Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022. GlobalData believes that relative patient share for the three MenC conjugate vaccines available in Australia will remain unchanged for the duration of the forecast period because Nuron Biotechs Meningitec, Novartis Menjugate, and Baxters NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Australia and therefore is not expected to change drastically during the forecast period. Scope Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in Australia including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in Australia from 2012-2022. Analysis of the impact of key events as well the drivers and restraints affecting Australia Meningococcal Vaccines market. Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales forecast for drugs from 2012-2022 in Australia table Of Contents 1 Table Of Contents 1 1.1 List Of Tables 3 1.2 List Of Figures 3 2 Executive Summary 4 2.1 Sales For Meningococcal Vaccine In Australia 4 PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022
  2. 2. 2.2 What Do The Physicians Think? 5 3 Introduction 6 3.1 Catalyst 6 3.2 Related Reports 7 3.3 Upcoming Related Reports 9 4 Disease Overview 9 4.1 Etiology And Pathophysiology 10 4.1.1 Etiology 10 4.1.2 Pathophysiology 11 4.2 Symptoms 13 4.3 Prognosis 14 5 Disease Management 14 5.1 Meningococcal Immunization Policy 15 5.2 Australia 17 5.2.1 Meningococcal Immunization Recommendations And Policies 17 5.2.2 Clinical Practice 19 6 Competitive Assessment 19 6.1 Overview 19 6.2 Strategic Competitor Assessment 20 6.3 Product Profiles Major Brands 21 6.3.1 Menactra 21 6.3.2 Menveo 26 6.3.3 Menitorix 30 6.3.4 Meningitec 33 6.3.5 Menjugate 36 6.3.6 Neisvac-c 39 6.3.7 Menomune 42 6.3.8 Bexsero 45 7 Opportunity And Unmet Need 47 7.1 Overview 47 7.2 Unmet Needs 48 7.2.1 Unmet Need: Protection Against Serogroup B Disease 48 7.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 48 PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022
  3. 3. 7.2.3 Unmet Need: More Cost-effective Vaccines 50 7.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 50 7.2.5 Unmet Need: Immunogenic Infant Vaccines 52 7.2.6 Unmet Need: Improved Vaccination Coverage Rates 53 7.2.7 Unmet Need: Increased Patient Awareness And Education 54 7.3 Unmet Needs Gap Analysis 55 7.4 Opportunities 56 7.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 56 7.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 57 7.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging Markets 58 8 Pipeline Assessment 58 8.1 Overview 58 8.2 Promising Vaccines In Clinical Development 58 8.2.1 Mnb Rlp2086 62 8.3 Promising Vaccines In Early Clinical Development 67 8.3.1 Meninge Acyw Conj. 68 8.3.2 Menabcwy 72 8.3.3 Menc Conjugate 75 8.3.4 Heptavalent Dtp-hib-hepb-ipv-menc 78 9 Market Outlook 80 9.1 Australia 80 9.1.1 Forecast 80 9.1.2 Key Events 83 9.1.3 Drivers And Barriers 84 10 Appendix 85 10.1 Bibliography 85 10.2 Abbreviations 97 10.3 Methodology 99 10.4 Forecasting Methodology 99 10.4.1 Vaccine Coverage 100 10.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 100 10.4.3 Vaccines Included 101 10.4.4 General Pricing Assumptions 102 10.4.5 Individual Vaccine Assumptions 103 10.4.6 Pricing Of Pipeline Agents 109 10.5 Physicians And Specialists Included In This Study 110 PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022
  4. 4. 10.6 About The Authors 114 10.6.1 Authors 114 10.6.2 Reviewers 114 10.6.3 Global Head Of Healthcare 114 10.7 About Globaldata 116 10.8 Contact Us 116 10.9 Disclaimer 116 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022

×